IceCure Medical Ltd.

We are a commercial-stage medical device company that researches and develops cryoablation systems and disposable products using liquid nitrogen (LN2) to treat tumors. Cryoablation is a process that destroys benign and malignant tumors, nerves, or other tissues by freezing them inside a patient's body. Our cryoablation technology offers a minimally invasive alternative to surgery for tumors in areas like the breast, lungs, kidneys, bones, and other tissues. It is also used for nerve ablation to manage pain and treat conditions such as endometriosis. Our main commercial cryoablation product is the ProSense system and its associated CryoProbes. The FDA has authorized the ProSense system for marketing for the local treatment of low-risk breast cancer, when combined with adjuvant endocrine therapy, in women aged 70 and above, including those unsuitable for surgical alternatives. We are also developing new products, including the XSense system with CryoProbes, which has received 510(k) regulatory clearance from the FDA. We believe the XSense system can serve as a platform for developing other unique CryoProbes and catheters, expanding our clinical applications. Our product pipeline also includes MSense, which could enable the treatment of multiple and larger tumors.